论文部分内容阅读
目的检测系统性红斑狼疮(SLE)患者血清黏附分子中可溶性血管细胞黏附分子-1(sVCAM-1)、可溶性细胞间黏附分子-1(sICAM-1)的水平,并探讨其临床意义。方法采用酶联免疫吸附试验(ELISA)法,检测30名健康人和60例SLE患者血清sVCAM-1、sICAM-1水平,以分析其与SLE活动性变化关系。结果①SLE患者血清sVCAM-1平均水平为2342ng/ml,显著高于正常人对照组1240ng/ml(P<0.001)。②SLE患者中血清sICAM-1平均水平为802ng/ml,显著高于正常人对照组626ng/ml(P<0.001)。③SLE患者中,血清sVCAM-1水平活动期高于稳定期(P<0.05),sICAM-水平活动期高于稳定期(P<0.05)。④SLE组血清sVCAM-1和sICAM-1水平与SLE病情活动指数(SLEDAI)、抗dsDNA抗体水平及尿蛋白的发生呈正相关,与血清补体C3水平呈负相关。结论sVCAM-1,sICAM-1可能参与SLE发病机制。
Objective To detect the levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular adhesion molecule-1 (sICAM-1) in patients with systemic lupus erythematosus (SLE) and to investigate its clinical significance. Methods Serum levels of sVCAM-1 and sICAM-1 in 30 healthy people and 60 SLE patients were detected by enzyme-linked immunosorbent assay (ELISA) to analyze their relationship with SLE activity. Results ① The average level of serum sVCAM-1 in SLE patients was 2342 ng / ml, which was significantly higher than that in normal controls (1240 ng / ml, P <0.001). ② The mean level of serum sICAM-1 in patients with SLE was 802ng / ml, which was significantly higher than that in normal controls (626ng / ml, P <0.001). (3) The activity of sVCAM-1 in sera was higher than that in stable (P <0.05), sICAM-level was higher than that in stable (P <0.05). ④ The level of serum sVCAM-1 and sICAM-1 in SLE group was positively correlated with SLEDAI, anti-dsDNA antibody level and urine protein, and negatively correlated with serum complement C3 level. Conclusion sVCAM-1 and sICAM-1 may participate in the pathogenesis of SLE.